Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients

Chronic Hepatitis C Clinical Trial

Official title:

Comparison of Standard Therapy,Peginterferon Alpha-2a + Ribavirin for 48 Weeks VS Peginterferon Alph-2a + Ribavirin + Betaine for 12 Weeks Followed by 36 Weeks Standard Therapy in Untreated Adults With Chronic Hepatitis C Genotype 1

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00571714
• Other study ID #: 0159-07-FB
• Status: Withdrawn
• Phase: N/A
• Start date: April 1, 2008
• Est. completion date: March 4, 2010

Study information

• Verified date: August 2023
• Source: University of Nebraska
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary purpose of the study is to compare the safety and effectiveness of standard treatment for chronic hepatitis C using peginterferon alpha-2a (Pegasys) and ribavirin (Copegus) to those same medications plus a dietary supplement called betaine when added for the first 12 weeks of treatment.

Peginterferon alpha-2a (Pegasys) and ribavirin (Copegus) are approved by the FDA (Food and Drug Administration) for the treatment of chronic hepatitis C.

Betaine is a dietary supplement and occurs naturally in the body. It is not a medication regulated by the FDA or an approved drug for chronic hepatitis C.

Description:

Although pegylated alpha interferon and ribavirin will likely be part of the core therapy for chronic HCV for the next several years, there are a number of complimentary antiviral agents in development including protease or polymerase inhibitors, RNA vaccines and immunomodulators (5). However, it would be unlikely to have FDA approval for any of these newer agents before the next 3 - 5 years, i.e. 2010-2012.

Betaine, a naturally occurring anti-oxidant metabolite of choline and an amino acid analog (tri-methyl-glycine), serves as a methylation agent to re-methylate damaged cell proteins or enzymes (6). By virtue of its metabolic role in decreasing toxic metabolites, betaine also protects against alcohol-induced fatty liver and apoptosis. Recently, pilot studies performed both at the Mayo Clinic and here at UNMC showed its applicability as a treatment of non-alcoholic fatty liver in human subjects (7, 8).

Betaine has also recently been found to promote interferon function by overcoming HCV - induced inhibition of interferon signaling (9). Naturally-occurring HCV proteins during human infection can hypo-methylate proteins integral to the Jak - STAT (signal transducers and activators of transcription) pathway, thereby inhibiting the antiviral activity of interferon. In cultured cells betaine administration, in a physiologically attainable concentration, restored STAT methylation and improved interferon signaling (9).

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: March 4, 2010
• Est. primary completion date: March 4, 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years to 70 Years

Eligibility

Inclusion Criteria:

• Subject must be willing to give informed consent and be able to adhere to dose and visit schedules.

• History of chronic hepatitis C as documented by either anti-HCV or HCV RNA positivity.

• Adult subjects 19-70 years of age, of either gender

• Liver biopsy within 3 years prior to the screening 1 visit.

• Compensated liver disease with the following maximum hematologic, biochemical and serologic criteria at the Screening visit (WNL=within normal limits) Hemoglobin > 12 g/dl for females and >13 g/dl for males, WBC > 3000/mm3, Platelets > 80,000/mm3, Direct Bilirubin - WNL. Indirect bilirubin - WNL, Albumin - WNL, Serum Creatinine - WNL.

• Fasting glucose should be 70 -140 mg/dl, results between 116-140 require a HbA1c < 8.5%

• TSH - WNL

• Subjects with a history of mild depression may be considered for entry in to this study provided that a pretreatment assessment of the subject's affective status supports that the subject is clinically stable.

• Subjects with a history of substance abuse must have abstained from using the substance for at least one year prior to the Screening visit.

• Antinuclear antibodies (ANA) < 1:320

• No radiologic evidence of a focal mass suggestive of hepatoma and/or ascites.

Exclusion Criteria:

• Pregnant or nursing subjects. Subjects who intend to become pregnant during the study period. Subjects with partners who intend to become pregnant during the study period.

• History of new hepatitis C exposure within the last 6 months

• Prior treatment for chronic hepatitis C.

• Current or intended use of G-CSF and/or GM-CSF during the stud period is prohibited. Current use of erythropoietin (EPO) is prohibited.

• Suspected hypersensitivity to any interferon product or ribavirin

• Participation in any other clinical trial within 30 days of Screening visit

• Treatment with any investigational drug within 30 days of Screening visit 1.

• Any other cause for liver disease other than CHC.

• Coagulopathies including hemophilia

• Hemoglobinopathies

• G6PD deficiency

• Coinfection with HIV and/or HBV

• Evidence of active or suspected malignancy or a history of malignancy within the last five years (with the exception of adequately treated basal cell carcinoma of the skin).

• Evidence of decompensated liver disease such as history or presence of ascites, bleeding varices or hepatic encephalopathy

• Subjects with organ transplants other than cornea or hair transplant

• Any Known preexisting medical condition, that could interfere with the subject's participation in and completion of the study.

Related Conditions & MeSH terms

• Chronic Hepatitis C
• Hepatitis
• Hepatitis A
• Hepatitis C
• Hepatitis C, Chronic
• Hepatitis, Chronic

Intervention

Drug:
• Peginterferon alpha-2a and ribavirin
Peginterferon alpha-2a 180mcg by subcutaneous injection every week and weight based ribavirin, 800 to 1400mg/day by mouth in two divided doses every day for 48 weeks
• Peginterferon alpha-2a , ribavirin and betaine
Peginterferon alpha-2a 180mcg given by subcutaneous injection every week plus weight based ribavirin 800 to 1400 mg/day by mouth in divided doses twice a day plus betaine 10 gm dissolved in juice twice a day for twelve weeks followed by peginterferon alpha-2a 180 mcg given by subcutaneous injection every week plus weight based ribavirin 800 to 1400mg/day by mouth in divided doses twice a day for 36 weeks.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University of Nebraska

References & Publications (3)

8. Mukherjee S, Bernard T, Schafer D, et al. Impact of betaine on hepatic fibrosis and homocysteine in nonalcoholic steatohepatitis: a prospective cohort study [abstract]. Hepatology 2005; 42: 610A.

Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol. 2001 Sep;96(9):2711-7. doi: 10.1111/j.1572-0241.2001.04129.x. — View Citation

Duong FH, Christen V, Filipowicz M, Heim MH. S-Adenosylmethionine and betaine correct hepatitis C virus induced inhibition of interferon signaling in vitro. Hepatology. 2006 Apr;43(4):796-806. doi: 10.1002/hep.21116. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sustained Viral Response 24 weeks following the end of anti-viral therapy	no patients enrolled	72 weeks
Secondary	Comparison of rapid and early virologic response in the first 4 and 12 weeks of therapy	no patients enrolled	12 weeks
Secondary	Comparison of the safety of the two treatment regimens	no patients enrolled	48 weeks
Secondary	Comparison of ALT normalization between the two regimens	no patients enrolled	48 weeks
Secondary	Comparison of the effect on interferon gene signaling in peripheral blood mononuclear cells between the two regimens in the first 12 weeks of therapy.	no patients enroll	12 weeks